Issue of Equity and Total Voting Rights

SkinBioTherapeutics PLC

16 October 2024

 

16 October 2024

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

Issue of Equity and Total Voting Rights

SkinBioTherapeutics plc, (AIM: SBTX, or the "Company"), the life science business focused on skin health, announces that it has issued, conditional on admission, 2,349,624 new ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares"), pursuant to the subscription agreement entered into by the Company and an existing shareholder announced on 11 October 2024.

The new Ordinary Shares will rank pari passu with the existing Ordinary Shares in issue and application has been made for the new Ordinary Shares to be admitted to trading on the AIM Market of the London Stock Exchange ("Admission"). Admission is expected to occur, and dealings in the new Ordinary Shares commence, at 8:00 a.m. on 17 October 2024.

Total Voting Rights

Following Admission, the Company will have 228,435,909 Ordinary Shares in issue. This figure of 228,435,909 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

-Ends-

For more information please contact:

SkinBioTherapeutics plc Stuart J. Ashman, CEO Manprit Randhawa, CFO	Tel: [phone]
Cavendish Capital Markets Limited (Nominated Adviser & Broker) Giles Balleny, Dan Hodkinson (Corporate Finance) Charlie Combe (Broking) Dale Bellis, Tamar Cranford-Smith (Sales)	Tel: [phone]
Vigo Consulting (financial press) Rozi Morris	[phone] [phone] [e-mail]

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix^®, is based upon discoveries made by the translational dermatology team at the University of Manchester.

The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AxisBiotix-Ps™, a food supplement to address the symptoms of mild to moderate psoriasis.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com and www.axisbiotix.com.

 

END